SI3297654T1 - Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39) - Google Patents

Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)

Info

Publication number: SI3297654T1
Authority: SI; Slovenia
Prior art keywords: exendin; post; treatment; bariatric hypoglycemia; bariatric
Prior art date: 2015-05-22

Application number

SI201631300T

Other languages

English (en)

Inventor

Tracey L. MCLAUGHLIN

Colleen M. Craig

Original Assignee

The Board Of Trustees Of The Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-22

Filing date

2016-05-23

Publication date

2021-11-30

2016-05-23 Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University

2021-11-30 Publication of SI3297654T1 publication Critical patent/SI3297654T1/sl

Links

WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 title 1
208000013016 Hypoglycemia Diseases 0.000 title 1
108010024703 exendin (9-39) Proteins 0.000 title 1
230000002218 hypoglycaemic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

SI201631300T 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39) SI3297654T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562165743P	2015-05-22	2015-05-22
US201562254175P	2015-11-11	2015-11-11
US201662329850P	2016-04-29	2016-04-29
PCT/US2016/033837 WO2016191395A1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)
EP16800621.1A EP3297654B1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number	Publication Date
SI3297654T1 true SI3297654T1 (sl)	2021-11-30

Family

ID=57393681

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201631300T SI3297654T1 (sl)	2015-05-22	2016-05-23	Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)
SI201631362T SI3297653T1 (sl)	2015-05-22	2016-05-23	Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201631362T SI3297653T1 (sl)	2015-05-22	2016-05-23	Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1

Country Status (18)

Country	Link
US (10)	US10660937B2 (sl)
EP (4)	EP3936143A1 (sl)
AU (6)	AU2016267057B2 (sl)
BR (2)	BR112017024997A2 (sl)
CA (2)	CA3024353A1 (sl)
CL (2)	CL2017002913A1 (sl)
CY (2)	CY1124616T1 (sl)
DK (2)	DK3297654T3 (sl)
ES (2)	ES2897955T3 (sl)
HR (2)	HRP20211768T1 (sl)
HU (2)	HUE057301T2 (sl)
LT (2)	LT3297654T (sl)
PL (2)	PL3297653T3 (sl)
PT (2)	PT3297653T (sl)
RS (2)	RS62627B1 (sl)
SI (2)	SI3297654T1 (sl)
SM (2)	SMT202100668T1 (sl)
WO (2)	WO2016191395A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4049673A1 (en)	2007-01-08	2022-08-31	The Trustees of the University of Pennsylvania	Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
HRP20211768T1 (hr)	2015-05-22	2022-02-18	The Board Of Trustees Of The Leland Stanford Junior University	Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1
WO2017152014A1 (en)	2016-03-04	2017-09-08	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt)	2016-11-21	2019-08-20	Eiger Biopharmaceuticals Inc	formulações tamponadas de exendina (9-39)
CN111936159A (zh) *	2018-01-23	2020-11-13	Xeris药物公司	使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症
GB201816639D0 (en) *	2018-10-12	2018-11-28	Heptares Therapeutics Ltd	GLP-1 Receptor Antagonist
BR112021006968A2 (pt) *	2018-10-15	2021-07-27	Eiger Biopharmaceuticals, Inc	avexitide para o tratamento da hipoglicemia hiperinsulinêmica
US20220088144A1 (en) *	2019-01-11	2022-03-24	Universitätsspital Basel	Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) *	2022-08-21	2024-02-29	M. Arkin (1999) Ltd	Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0154880B1 (ko)	1992-06-15	1998-10-15	피터 알.셰어러	글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en)	1996-08-06	2004-05-13	Yeda Research And Development Co., Ltd	Long-acting exendins and exendin agonists
ES2319936T5 (es)	1996-08-08	2013-06-24	Amylin Pharmaceuticals, Inc.	Regulación de la motilidad gastrointestinal
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
JP4798814B2 (ja)	1997-01-07	2011-10-19	アミリン・ファーマシューティカルズ，インコーポレイテッド	食物摂取低減用のエキセンジンおよびそのアゴニストの使用
PL191327B1 (pl)	1998-01-30	2006-04-28	Novo Nordisk As	Strzykawka do podawania ustalonych dawek lekarstwa z naboju
NZ511698A (en)	1998-12-10	2003-09-26	Agouron Pharma	Pyrrolo-pyridine antagonists of GLP-1 receptor
DK1140145T4 (da)	1999-01-14	2019-07-22	Amylin Pharmaceuticals Llc	Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
ES2343072T3 (es)	1999-01-14	2010-07-22	Amylin Pharmaceuticals, Inc.	Exendina para la supresion del glucagon.
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6903074B1 (en)	1999-06-04	2005-06-07	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Neuromedin b and somatostatin receptor agonists
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
US6479065B2 (en)	2000-08-10	2002-11-12	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en)	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv)	2000-12-04	2000-12-04	Pharmacia Ab	Novel method and use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
US7638598B2 (en)	2001-04-06	2009-12-29	The Trustees Of The University Of Pennsylvania	ErbB interface peptidomimetics and methods of use thereof
CN1162446C (zh)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	促胰岛素分泌肽衍生物
GB0113179D0 (en)	2001-05-31	2001-07-25	Novartis Ag	Organic compounds
CA2452044A1 (en)	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
US7378385B2 (en)	2002-08-08	2008-05-27	University Of Cincinnati	Role for GLP-1 to mediate responses to disparate stressors
US7208514B2 (en)	2003-03-13	2007-04-24	Mitsubishi Pharma Corporation	Tumorigenesis inhibitor
CN1882356B (zh)	2003-11-20	2015-02-25	诺沃挪第克公司	对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US7456254B2 (en)	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
CN1968700A (zh)	2004-04-15	2007-05-23	阿尔克姆斯有限公司	聚合物基的持续释放装置
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
CA2609810C (en)	2005-06-06	2012-05-22	Camurus Ab	Glp-1 analogue formulations
JP5693817B2 (ja)	2005-08-19	2015-04-01	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	糖尿病の治療法および体重の減少法
BRPI0710826A2 (pt)	2006-04-21	2011-08-23	Novartis Ag	composições farmacêuticas de anticorpo anti-cd40 antagonista
WO2007139941A2 (en)	2006-05-26	2007-12-06	Amylin Pharmaceuticals, Inc.	Composition and methods for treatment of congestive heart failure
EP4049673A1 (en)	2007-01-08	2022-08-31	The Trustees of the University of Pennsylvania	Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
DE102007016811A1 (de)	2007-04-05	2008-10-09	Tecpharma Licensing Ag	Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
JP5128658B2 (ja)	2007-04-05	2013-01-23	テクファーマ・ライセンシング・アクチェンゲゼルシャフト	機能的な駆動素子を備える投与装置
RU2440097C2 (ru)	2007-04-23	2012-01-20	Интарсия Терапьютикс, Инк.	Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
BRPI0908292B1 (pt)	2008-05-05	2022-09-20	Oramed Ltd	Métodos e composições para administração oral de exenatida
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
JP5622725B2 (ja)	2008-06-25	2014-11-12	エンドファーマスーティカルズソリューションズインコーポレイテッド．ＥｎｄｏＰｈａｒｍａｃｅｕｔｉｃａｌｓＳｏｌｕｔｉｏｎｓｉｎｃ．	エキセナチド及び他のポリペプチド類の持続的送達
EP2310042B1 (en) *	2008-07-08	2012-12-05	Novartis AG	Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
SMT202000405T1 (it)	2008-09-04	2020-09-10	Amylin Pharmaceuticals Llc	Formulazioni a rilascio prolungato usando veicolanti non acquosi
MX2011010454A (es)	2009-04-03	2012-01-25	Nestec Sa	Mejoramiento en la promocion de la sana recuperacion del crecimiento.
EP2440228B8 (en)	2009-06-08	2023-02-22	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
WO2011109787A1 (en)	2010-03-05	2011-09-09	Conjuchem, Llc	Methods of administering insulinotropic peptides
WO2012012352A2 (en)	2010-07-19	2012-01-26	Amidebio, Llc	Modified peptides and proteins
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en)	2011-10-18	2014-09-11	Prolynx Llc	Peg conjugates of exenatide
EP2817025A2 (en)	2012-02-08	2014-12-31	Seneb Biosciences, Inc.	Treatment of hypoglycemia
JP6265970B2 (ja)	2012-03-26	2018-01-24	サノフイ	安定なＩｇＧ４に基づく結合剤の製剤
HK1226084A1 (zh)	2013-08-16	2017-09-22	Medimmune Limited	用於治疗糖尿病的gip和glp-1受体双重激动剂
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
HRP20211768T1 (hr)	2015-05-22	2022-02-18	The Board Of Trustees Of The Leland Stanford Junior University	Liječenje postbarijatrijske hipoglikemije s antagonistima glp-1
WO2017152014A1 (en)	2016-03-04	2017-09-08	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt)	2016-11-21	2019-08-20	Eiger Biopharmaceuticals Inc	formulações tamponadas de exendina (9-39)
AU2023320411A1 (en)	2022-08-05	2025-01-30	Indiana University Research And Technology Corporation	Glucagon-like peptide-1 receptor antagonists

2016
- 2016-05-23 HR HRP20211768TT patent/HRP20211768T1/hr unknown
- 2016-05-23 EP EP21176474.1A patent/EP3936143A1/en active Pending
- 2016-05-23 SI SI201631300T patent/SI3297654T1/sl unknown
- 2016-05-23 HR HRP20211285TT patent/HRP20211285T1/hr unknown
- 2016-05-23 US US15/576,646 patent/US10660937B2/en active Active
- 2016-05-23 ES ES16800620T patent/ES2897955T3/es active Active
- 2016-05-23 CA CA3024353A patent/CA3024353A1/en active Pending
- 2016-05-23 LT LTEPPCT/US2016/033837T patent/LT3297654T/lt unknown
- 2016-05-23 SM SM20210668T patent/SMT202100668T1/it unknown
- 2016-05-23 RS RS20211458A patent/RS62627B1/sr unknown
- 2016-05-23 HU HUE16800620A patent/HUE057301T2/hu unknown
- 2016-05-23 AU AU2016267057A patent/AU2016267057B2/en active Active
- 2016-05-23 PL PL16800620T patent/PL3297653T3/pl unknown
- 2016-05-23 DK DK16800621.1T patent/DK3297654T3/da active
- 2016-05-23 CA CA3024358A patent/CA3024358A1/en active Pending
- 2016-05-23 PT PT16800620T patent/PT3297653T/pt unknown
- 2016-05-23 SI SI201631362T patent/SI3297653T1/sl unknown
- 2016-05-23 WO PCT/US2016/033837 patent/WO2016191395A1/en not_active Ceased
- 2016-05-23 BR BR112017024997-9A patent/BR112017024997A2/pt not_active Application Discontinuation
- 2016-05-23 AU AU2016267052A patent/AU2016267052B2/en active Active
- 2016-05-23 EP EP21194982.1A patent/EP3978011A1/en active Pending
- 2016-05-23 PL PL16800621T patent/PL3297654T3/pl unknown
- 2016-05-23 US US15/576,647 patent/US10639354B2/en active Active
- 2016-05-23 EP EP16800621.1A patent/EP3297654B1/en active Active
- 2016-05-23 BR BR112017025000-4A patent/BR112017025000A2/pt not_active Application Discontinuation
- 2016-05-23 ES ES16800621T patent/ES2887723T3/es active Active
- 2016-05-23 LT LTEPPCT/US2016/033836T patent/LT3297653T/lt unknown
- 2016-05-23 PT PT168006211T patent/PT3297654T/pt unknown
- 2016-05-23 RS RS20211073A patent/RS62368B1/sr unknown
- 2016-05-23 EP EP16800620.3A patent/EP3297653B1/en active Active
- 2016-05-23 WO PCT/US2016/033836 patent/WO2016191394A1/en not_active Ceased
- 2016-05-23 HU HUE16800621A patent/HUE055728T2/hu unknown
- 2016-05-23 DK DK16800620.3T patent/DK3297653T3/da active
- 2016-05-23 SM SM20210488T patent/SMT202100488T1/it unknown
2017
- 2017-11-16 CL CL2017002913A patent/CL2017002913A1/es unknown
- 2017-11-16 CL CL2017002911A patent/CL2017002911A1/es unknown
2020
- 2020-03-09 US US16/813,536 patent/US10993992B2/en active Active
- 2020-03-09 US US16/813,535 patent/US10993991B2/en active Active
2021
- 2021-04-09 US US17/226,164 patent/US11617782B2/en active Active
- 2021-04-09 US US17/226,161 patent/US11622995B2/en active Active
- 2021-09-01 CY CY20211100779T patent/CY1124616T1/el unknown
- 2021-11-29 CY CY20211101046T patent/CY1125147T1/el unknown
2022
- 2022-03-22 AU AU2022201973A patent/AU2022201973B2/en active Active
- 2022-04-14 AU AU2022202506A patent/AU2022202506B2/en active Active
2023
- 2023-02-22 US US18/172,543 patent/US12220444B2/en active Active
- 2023-02-22 US US18/172,546 patent/US12102663B2/en active Active
2024
- 2024-06-17 US US18/745,091 patent/US20250082730A1/en active Pending
2025
- 2025-01-02 US US19/008,248 patent/US20250255935A1/en active Pending
- 2025-08-13 AU AU2025217292A patent/AU2025217292A1/en active Pending
- 2025-08-22 AU AU2025220813A patent/AU2025220813A1/en active Pending

Also Published As

Publication number	Publication date
CY1125147T1 (el)	2023-03-24
SMT202100668T1 (it)	2022-01-10
US11622995B2 (en)	2023-04-11
EP3978011A1 (en)	2022-04-06
WO2016191394A1 (en)	2016-12-01
US12102663B2 (en)	2024-10-01
AU2022201973B2 (en)	2025-05-15
CA3024353A1 (en)	2016-12-01
LT3297653T (lt)	2022-01-10
US11617782B2 (en)	2023-04-04
EP3297653B1 (en)	2021-09-15
CA3024358A1 (en)	2016-12-01
PT3297653T (pt)	2021-10-25
ES2897955T3 (es)	2022-03-03
SI3297653T1 (sl)	2022-01-31
HRP20211768T1 (hr)	2022-02-18
US20240000894A1 (en)	2024-01-04
HRP20211285T1 (hr)	2022-01-07
AU2025217292A1 (en)	2025-09-04
AU2016267057B2 (en)	2021-12-23
US20230346890A1 (en)	2023-11-02
US10660937B2 (en)	2020-05-26
EP3297654A1 (en)	2018-03-28
DK3297654T3 (da)	2021-09-06
RS62368B1 (sr)	2021-10-29
US20200276272A1 (en)	2020-09-03
HUE057301T2 (hu)	2022-05-28
US20180117122A1 (en)	2018-05-03
US20210290731A1 (en)	2021-09-23
BR112017025000A2 (pt)	2018-08-07
AU2016267052A1 (en)	2017-12-14
CL2017002913A1 (es)	2018-06-01
BR112017024997A2 (pt)	2018-07-31
EP3936143A1 (en)	2022-01-12
US20210315974A1 (en)	2021-10-14
AU2022201973A1 (en)	2022-04-14
US20200276271A1 (en)	2020-09-03
AU2022202506B2 (en)	2025-06-05
AU2016267057A1 (en)	2017-12-14
AU2022202506A1 (en)	2022-05-12
US20180147261A1 (en)	2018-05-31
WO2016191395A1 (en)	2016-12-01
US10993991B2 (en)	2021-05-04
ES2887723T3 (es)	2021-12-27
RS62627B1 (sr)	2021-12-31
US20250082730A1 (en)	2025-03-13
EP3297654B1 (en)	2021-07-07
US20250255935A1 (en)	2025-08-14
AU2016267052B2 (en)	2022-01-20
SMT202100488T1 (it)	2021-11-12
US10993992B2 (en)	2021-05-04
AU2025220813A1 (en)	2025-09-11
CL2017002911A1 (es)	2018-05-25
EP3297653A1 (en)	2018-03-28
US12220444B2 (en)	2025-02-11
PL3297653T3 (pl)	2022-01-31
US10639354B2 (en)	2020-05-05
EP3297653A4 (en)	2018-12-26
DK3297653T3 (da)	2021-10-18
PT3297654T (pt)	2021-09-06
LT3297654T (lt)	2021-10-25
CY1124616T1 (el)	2022-07-22
HUE055728T2 (hu)	2021-12-28
PL3297654T3 (pl)	2021-12-20
EP3297654A4 (en)	2018-04-11

Publication	Publication Date	Title
PT3297654T (pt)	2021-09-06	Tratamento de hipoglicemia pós-bariátrica com exendina(9-39)
SG10202100803WA (en)	2021-03-30	Endoscope with pannable camera and related method
ZA201706059B (en)	2023-08-30	Method of treatment with tradipitant
GB201502137D0 (en)	2015-03-25	Treatment
IL252803B (en)	2022-04-01	Formulation with a constant ratio of insulin glargine/licisanitide
GB201522243D0 (en)	2016-01-27	Treatment
IL254825A0 (en)	2017-12-31	Methods of treatment with Tesalisib
GB201519450D0 (en)	2015-12-16	Novel treatment
GB201508841D0 (en)	2015-07-01	Treatment
SI3139948T1 (sl)	2020-07-31	Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
IL247218A0 (en)	2016-09-29	Treatment of infections caused by h. pylori using mtan inhibitors
GB201513543D0 (en)	2015-09-16	Compositions for use in the treatment of diabetes
GB201503008D0 (en)	2015-04-08	Treatment
GB201414366D0 (en)	2014-09-24	Blood defence
AU2015904246A0 (en)	2015-11-05	Treatment of diabetes
HUE048860T2 (hu)	2020-09-28	1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
AU2016901862A0 (en)	2016-06-02	Treatment of diabetes
GB201513922D0 (en)	2015-09-23	Treatment of hyperpigmentation
GB201518349D0 (en)	2015-12-02	Treatment
GB201515739D0 (en)	2015-10-21	Treatment
GB201514008D0 (en)	2015-09-23	Treatment
GB201604099D0 (en)	2016-04-20	Insulin biosensor
AU2015902668A0 (en)	2015-07-16	Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en)	2017-09-13	Agent for treating diabetes
GB201407396D0 (en)	2014-06-11	Confectionary treatment